In May 2007, an important meta-analysis by Nissen and Wolski was published in the New England Journal of Medicine in terms of cardiovascular (CV) safety of rosiglitazone. 1 The article examined studies of rosiglitazone using published articles and the database of the manufacturer (GlaxoSmithKline [GSK] Understandably, the study created a furore as it appeared to show an increase in MI risk for one of the more popular drugs used to treat diabetes. Given that earlier studies had shown favorable effects on multiple surrogate markers of CV risk, this was especially noteworthy.
sulfonylurea or metformin versus the combination of these two latter agents in 2,227 patients. The primary endpoint was a composite of hospitalization or death from CV causes. The analysis was performed after 3.75 years of follow-up. Of those studied with adjudicated primary endpoints, 217 patients in the rosiglitazone add-on arm and 202 patients in the control arm reached the adjudicated endpoint.
This resulted in a HR of 1.08 (95 % CI 0.89-1.31). Similar data were found by including subjects with events pending adjudication (HR 1.11, CI 0.93-1.32). One secondary endpoint in the interim RECORD analysis was significantly positive and that was congestive heart failure (CHF). In the rosiglitazone arm, 47 patients were hospitalized for CHF versus 22 for the control group with a HR for both adjudicated and pending adjudication that was significant (HR for both combined 2.15, CI 1.30-3.57). The RECORD trial itself had some potential problems with its own analysis as the expected proportion of subjects with primary endpoint events (11 %) for adequate power was considerably higher than the actual proportion during the study (closer to 2.5 %), making the study have a higher likelihood of an indeterminate result for the primary endpoint.
Other papers have been published that have attempted to use alternative analytical approaches and see if they could confirm the Nissen paper or not. Concerns about the number of short-term studies incorporated into the original Nissen paper model approach used led
Diamond and colleagues 5 to analyze the statistical methods used by Nissen. They found additional problems that led them to conclude there was no ability to declare whether rosiglitazone had increased or decreased CV death or MI risk. Some of Diamond's critique is related to the exclusion of trials (n=6) with no events in an unknown number of subjects, the lack of focus on trials that were rosiglitazone monotherapy versus control (which may be considered the cleanest kind of an analysis), the use of studies with active comparators with potential benefit to CV death or MI risk (e.g. metformin), the absence of data on stroke or non-CV death, and inadequate detail about the literature search methods used by Nissen. The primary focus of the critique by Diamond et al. was first on the use of a fixed model (Peto method) for analysis. The second statistical focus was on the choice of a Cochran Q test to justify pooled data from many heterogeneous studies and populations studied-in effect to show that they were nonetheless statistically not too heterogeneous to be lumped together.
This second critique can be exemplified by asking whether it was acceptable to pool rosiglitazone studies of patients with Alzheimer's disease or psoriasis with those of patients with pre-diabetes and diabetes and tentatively concludes that these were potentially improper methods. Similarly, it was questioned whether pooling data from diabetes patients with and without heart disease was analytically incorrect as the diagnosis might interact with the endpoints of interest, such as CV death or MI. It is important to draw a distinction between absolute and RR in these studies. A neglected area of discussion with these meta-analyses and other studies in the presentation of CV risk results is the overuse and emphasis on RRs and the minimization of absolute risks. The latter gives a much more balanced picture of risks and benefits than the RRs do. This problem was particularly egregious in the publicity that reached the general public. The headlines about the original Nissen analysis trumpeted summaries of 43 % increased risk for heart attack and 64 % increased risk for heart disease death. The absolute number of MI events was quite small between the original meta-analysis groups-MI was 86 out of 15,560 or 0.55 % for rosiglitazone and 72 out of 12,283 or 0.59 %. Such an inappropriate emphasis magnifies the perceived risk to an unwarranted degree. In a reductionist analogy, one could say that the risk with one treatment was doubled, but on the understanding that it went, for example, from one in a million to two in a million gives a profoundly different sense of the risk.
Nonetheless, given that heart disease is the primary cause of death, disability and cost in type 2 diabetes, any increase in that risk is clearly highly undesirable and if correctly estimated should lead to avoidance of a therapy that increases such risk.
Other Randomized Trials

Rosiglitazone Evaluated for Cardiovascular Outcomes
The final report of the RECORD trial 7 was similar to that of the earlier interim analysis. The primary endpoint of this study was time to the first CV hospitalization or death secondary to CV causes.
Hospitalizations were defined as admission for HF, cerebrovascular disease, cardiac revascularizations, amputation secondary to peripheral arterial disease (PAD), thrombotic events, and acute MIs (AMIs). These events were isolated by questionnaires and adverse event reporting at subject follow-up visits. Of note, the study was underpowered to determine non-inferiority of rosiglitazone. The event rate per year reached was only 2.5 % (not the expected 11 %), significantly reducing the power of the study's conclusions. RECORD found no difference in CV deaths between the rosiglitazone group and the comparator arm (rosiglitazone group HR 0.84, 95 % CI 0.59-1.18; p=0.32). There were also no differences in all-cause mortality between the two groups (rosiglitazone group HR 0.86; 95 % CI 0.68-1.08; p=0.19).
There was no increase in the primary endpoint in the TZD group 
Bypass Angioplasty Revascularization Investigation 2 Diabetes
The first Bypass angioplasty revascularization investigation (BARI) study, released in 1996, found that patients with diabetes treated with coronary artery bypass grafting (CABG) had a statistically significant improvement in five-year survival compared with those treated with percutaneous coronary intervention (PCI) (80.6 versus 65.5 %; p=0.003). 9 These findings led to the six-year, multicenter BARI 2D trial, released in June 2009 (see Table 1 ). 10 In BARI 2D, 2,368 subjects with type 2 diabetes and angiographically documented CHD were randomized to undergo coronary revascularization (PCI or CABG) or intensive medical therapy (IMT). Furthermore, patients received insulin-sensitization (IS) therapies (metformin, TZDs) or insulin-provision (IP) therapies (insulin, sulfonylureas), with a goal of attaining an glycated hemoglobin (HbA 1c ) level of less than 7 %.
The primary endpoint in BARI 2D was all-cause mortality, and a secondary endpoint included major CV events (death, MI, and stroke).
Events were adjudicated by a clinical events committee. A total of 82 % of patients had symptomatic myocardial ischemia, and the average duration of diabetes was approximately 10 years. Recruitment took longer than expected, and the study was extended by 1.5 years, increasing the average follow-up to 5.3 years. Those receiving IS medications (n=977) were using metformin (74.6 %) and TZDs (62.1 %). significance between the sensitization and provision groups, with the former having a non-significantly = fewer number of major CV events when undergoing revascularization (p=0.07).
In summary, the BARI 2D study showed no significant differences in the rates of major CV events and all-cause mortality between patients with type 2 diabetes randomized to early revascularization or IMT, and to those using an IS strategy (metformin, TZDs) for glucose control, and those using an IP strategy (insulin, sulfonylureas). However, the study findings did suggest that individuals undergoing early revascularization with CABG who were also taking IS agents had fewer adverse cardiac outcomes compared with those taking IP therapies.
Although we cannot generalize these results to the effects of TZDs alone on CV morbidity and mortality, they should be taken into account when determining the safety and clinical use of this drug class. It is hoped that future analyses of the BARI 2D data will tease apart the effects of the TZDs, specifically on CV risk.
The Action to Control Cardiovascular Risk in Diabetes Study and the Veterans Administration Diabetes Trial
It should be briefly noted that both the Action to control cardiovascular risk in diabetes (ACCORD) study 11 and the Veterans Administration diabetes trial (VADT) 12 tested whether CV death risk was reduced by intensive glycemic control. In their protocols there was heavy use of rosiglitazone with intensive glycemic treatment.
The 22 % increase in mortality in the ACCORD trial and no benefit to CV death risk in either study raised questions about whether the failure to show benefit might be explained by heavy use of rosiglitazone. Neither study could confirm this by post hoc statistical analyses. The ability to do so in such complex treatment studies is difficult at best and perhaps unachievable.
New Meta-analyses and Other Studies
A recent retrospective analysis cohort study 13 The results of this study found 8,667 endpoints in the study period. treated for one year. While AMI was not significant, the composite endpoint including it was significant for increased risk.
As is shown in p=0.04). The previous study had detected a strong trend to increased CV death risk (1.6; p=0.06), but the updated meta-analysis 14 did not detect a significant trend. In order to improve their methods in response to critiques, they performed their analysis with and without use of the RECORD trial, which had a small impact on their findings. They also 
Summary of several studies suggest overlap of tendency to harm versus uncertainty for rosiglitazone and tendency to benefit versus uncertainty for pioglitazone for cardiovascular death endpoints. CV = cardiovascular; FDA = US Food and Drug Administration; GSK = GlaxoSmithKline; HR = hazard ratio; IHD = ischemic heart disease; MI = myocardial infarction; OR = odds ratio; RR = risk ratio.
Source: Figure adapted from Erdman et al., 2009. 20 carried out an analysis with and without studies with no events and again found no significant differences in overall assessment of MI risk.
Mannucci and colleagues have performed meta-analyses of rosiglitazone and pioglitazone and written reviews about these two agents. 15, 16 Contrary to other such analyses they have argued that studies of neither drug have convincingly shown either benefit or harm to the CV system. In their analysis they studied 164 trials with a duration of more than four weeks (retrieved from [19] [20] Their analysis emphasizes the differences between these two agents and also the unknowns or partial data in terms of other diabetes oral medications (including the dipeptidyl peptidase-4
[DPP4] inhibitor incretins sitagliptin and vildagliptin), α-glucosidase inhibitors, metformin, and sulfonylureas. One of the figures in their review (see Figure 1) illustrates the differences between pioglitazone and rosiglitazone in terms of CV death risk and also illustrates the overlap between studies showing benefit or harm and those revealing uncertainty about CV death risk, which is a recurring theme of this review.
In a retrospective inception cohort study published recently by Wertz et al. 21 directly comparing rosiglitazone and pioglitazone with a propensity score-matched population that included mortality data, there were no differences found between these two agents in 36,628 Rosen's narrative suggests it is clear that more action needs to be taken because of the persistent concern raised by the remaining apparent increased risk for ischemic heart disease related to rosiglitazone. He argues that neither the marketplace nor FDA warnings have markedly influenced the sales of rosiglitazone, which remain steady, although substantially less than pioglitazone.
Conclusions
Several matters of ethics and scientific uncertainty are intertwined in the debate over rosiglitazone and its CV safety. The science suggests residual uncertainty whether rosiglitazone increases the risk for MI events despite credible concerns. The FDA mandated Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) study with not be completed or powered to provide the certainty needed.
What action should be taken in the absence scientific certainty?
Decision-makers should consider that RR compared with other therapies seems strongly suggestive of residual problems. It may be best to take a primum non nocere (first do no harm) approach. Do we harm patients more by leaving the drug on the market in the face of uncertain risk or more by removing an effective drug that may have more risk than seems reasonable, but less worrisome than alternatives? It seems necessary to act despite the scientific uncertainty, while recognizing that weak science makes for problematic policy decisions. Comparing rosiglitazone and pioglitazone one would say that there are fewer concerns about the latter drug for CV risk but has concerns about CHF and bone fracture risk probably equal to rosiglitazone. Whether it is appropriate to start new patients on rosiglitazone is questionable. The FDA (so far in its stance on the enrolment of patients in the TIDE trial) appear to be saying no unlike their stance in terms of pioglitazone and other non-TZD alternatives. No final decision from the FDA has yet been taken but inevitably it seems that rosiglitazone does not have a rosy future and that a preference for alternatives in the form of safer TZDs or peroxisome proliferator-activated receptors (PPARs) can be seen.
Selective modulators seem to be the way of the future. n
